Vyriad collaborates with Novartis to develop in vivo CAR-T cell therapies.

M2 EQUITYBITES-November 21, 2024-Vyriad collaborates with Novartis to develop in vivo CAR-T cell therapies

(C)2024 M2 COMMUNICATIONS https://www.m2.co.uk

Vyriad Inc, a US-based clinical-stage biotechnology company developing targeted genetic therapies, announced on Wednesday a strategic collaboration with Swiss pharmaceutical company Novartis Pharma AG (SIX:NOVN) (NYSE:NVS) to discover and develop in vivo chimeric antigen receptor (CAR) T-cell therapies.

This collaboration will leverage Vyriad's active targeting lentiviral vector platform and Novartis expertise and leadership in cell therapy innovation. Novartis and Vyriad will focus on the identification and development of in vivo CAR-T cell therapy candidates to be clinically advanced by Novartis. Vyriad will receive an upfront payment, milestone payments and tiered royalties on each programme.

Vyriad CEO Stephen J. Russell, M.D. Ph.D., said: "Taking an in vivo approach to CAR-T cell therapies has the potential to transform the field. We believe our targeted delivery platform is poised to enable this vision for the industry and our collaboration with Novartis represents an exciting step forward in advancing the next generation of CAR-T cell treatments."

((Comments on this story may be sent to [email protected]))